I. Total Body Iron Content & Distribution: A Functional Perspective
The adult human body contains 3–4 g of iron, tightly regulated via absorption, recycling, and storage mechanisms—not excretion (no active excretory pathway for iron). Iron is distributed as follows:
| Compartment | Quantity (g) | Clinical Relevance |
|---|---|---|
| Hemoglobin (Hb) | 2.0–2.5 g (≈70% total) | Primary functional pool; each gram Hb binds 1.34 mL O₂. A 1 g/dL drop in Hb corresponds to ~13.4 mL less O₂ carry capacity per dL blood. |
| Storage Iron | 0.5–1.0 g (≈25%) Ferritin (soluble) + Hemosiderin (insoluble) | Reflects total body iron reserves. Ferritin is the most practical surrogate marker—but confounded by inflammation (see Section VI). |
| Myoglobin | ~0.3 g (≈8%) | Oxygen storage in skeletal and cardiac muscle; depletion contributes to exercise intolerance & diastolic dysfunction. |
| Enzymes & Transport Proteins | ~0.1 g (≈2–3%) Cytochromes, catalase, peroxidases, transferrin, etc. | Supports mitochondrial respiration, DNA synthesis (ribonucleotide reductase), detoxification, and immune function. |
| Plasma Iron (transferrin-bound) | ~0.004 g (trace) | Dynamic pool in rapid exchange with storage & functional compartments. |
Key Insight: Even pre-anemic iron deficiency (normal Hb but low stores) impairs cellular energetics—e.g., reduced skeletal muscle oxidative phosphorylation, dopaminergic dysfunction (linked to restless legs syndrome), and impaired neurocognitive performance (Lozoff et al., Am J Clin Nutr 2022).
II. Etiology of Iron Deficiency: Beyond Blood Loss
While chronic blood loss remains the most common cause in adults, modern clinicians must consider nuanced mechanisms:
A. Blood Loss (Most Common Cause in Adults)
- GI Bleeding:
- Upper GI: NSAID-induced mucosal injury (COX-1 inhibition → reduced prostaglandin-mediated mucosal protection); H. pylori infection (even without ulcer; odds ratio for iron deficiency: 2.3, 95% CI 1.7–3.1) (Pellegrini et al., Gut 2020).
- Lower GI: Colorectal cancer (RR 4.8 in unexplained IDA; Lanas et al., Lancet Gastroenterol Hepatol 2023), angiodysplasia (especially in elderly, aortic stenosis—Heyde’s syndrome).
- Menstrual Blood Loss:
- Menorrhagia (>80 mL/period; objectively measured via pictorial blood loss assessment chart) accounts for IDA in 30–50% of premenopausal women (ACOG Practice Bulletin No. 224, 2023).
- Other: Frequent blood donation (>2 units/year; ferritin decline ≈12 μg/L per unit), frequent phlebotomy for therapeutic reasons.
B. Impaired Absorption / Increased Requirements
- Malabsorption:
- Celiac disease (up to 40% present with IDA as sole feature; Lebwohl et al., Gastroenterology 2021).
- Atrophic gastritis (autoimmune or H. pylori-induced) → hypochlorhydria → impaired non-heme iron solubilization.
- Bariatric surgery (especially Roux-en-Y; malabsorptive component > restrictive).
- Increased Demand:
- Pregnancy: Plasma volume expands by 50%, RBC mass by 25–30%; total iron requirement ≈1,000 mg. WHO recommends 30–60 mg elemental iron/day prophylaxis (WHO 2023 update).
- Adolescents: Peak bone & muscle growth (additive RBC mass expansion + menarche).
C. Dysregulated Iron Distribution: Anemia of Inflammation (AI) & Combined Deficiency
- In chronic disease (CKD, rheumatoid arthritis, cancer), hepcidin is upregulated by IL-6 → blocks basolateral iron efflux from enterocytes and macrophages via ferroportin degradation.
- Clinical Pitfall: Ferritin >100 μg/L does not exclude true iron deficiency—up to 30% of patients with CKD or IBD have functional iron deficiency (FID) despite “normal” ferritin (Nemeth & Ganz, Blood 2022).
- Diagnostic Strategy: Use combined biomarkers—see Section VI.
D. Parasitic Infections
- Hookworm (Ancylostoma duodenale, Necator americanus): Each worm consumes 0.03–0.15 mL blood/day; heavy infestations cause significant occult GI bleeding (WHO estimates 576 million infected globally; Ferris et al., PLoS NTD 2023).
- Schistosoma mansoni: Mucosal intestinal invasion → chronic blood loss.
III. Clinical Manifestations: From Subtle to Severe
| Symptom | Pathophysiology | Evidence Correlation |
|---|---|---|
| Fatigue, exercise intolerance | ↓ O₂ delivery → impaired mitochondrial ATP synthesis; skeletal muscle mitochondrial dysfunction (ferritin <30 μg/L) | Strongly associated even at Hb >12 g/dL (Olivier et al., J Intern Med 2021) |
| Pica (geophagia, pagophagia) | Dopaminergic hypoactivity in striatum; iron is cofactor for tyrosine hydroxylase | Pagophagia (ice craving) resolves rapidly with IV iron—often before Hb normalization (Watanabe et al., Sleep Med 2022) |
| Restless Legs Syndrome (RLS) | Iron-dependent dopamine synthesis in substantia nigra; CSF ferritin <25 μg/L in >80% of IDA-RLS | IV iron improves RLS severity scores by 50% within 4 weeks (Trenkwalder et al., Mov Disord 2023) |
| Glossitis, koilonychia, angular cheilitis | Impaired epithelial cell proliferation & keratinocyte differentiation due to iron-dependent enzyme dysfunction | Koilonychia correlates with ferritin <15 μg/L (specificity >90%) |
Note: Cardiovascular symptoms (tachycardia, systolic flow murmur, high-output heart failure) occur when Hb <7–8 g/dL; chronic severe IDA may cause left ventricular dilation and reduced ejection fraction (reversible with iron repletion).
IV. Diagnostic Workup: A Stepwise Algorithm
Initial Test (Suspected IDA): CBC + peripheral smear + reticulocyte count
- Microcytosis: MCV <80 fL is earliest lab abnormality—may precede Hb drop by weeks.
- Hypochromia: MCH <27 pg, MCHC <32 g/dL
- RDW >15%: Sensitive early marker (sensitivity 96% for iron deficiency before anemia develops) (Kottke-Marchant et al., Br J Haematol 2021)
Confirm Iron Deficiency: Serum Ferritin is the single best test—but interpret contextually:
| Ferritin (μg/L) | Interpretation |
|---|---|
| <30 | Definitive iron deficiency (sensitivity 92%, specificity 98%) |
| 30–100 | Indeterminate—check CRP/ESR; if ↑, consider functional ID |
| >100 | Iron deficiency unlikely unless inflammation is severe |
In Inflammatory States: Use:
- Transferrin Saturation (TSAT): <20% strongly suggests iron deficiency (AUC 0.94 for diagnosing true ID in rheumatoid arthritis; Finckh et al., Ann Rheum Dis 2023).
- sTfr-Ferritin Index: >2 suggests combined deficiency (valid in CKD, IBD, heart failure) (Peyrin-Biroulet et al., JGH Open 2024).
- Retired markers: soluble transferrin receptor (sTfR) is unreliable in acute inflammation; zinc protoporphyrin has limited utility.
When to Image?
- All men & postmenopausal women with IDA: Upper endoscopy + colonoscopy (per ACG 2023 guideline).
- Premenopausal women with menorrhagia: Pelvic US ± endometrial biopsy if abnormal bleeding persists after medical therapy.
V. Iron Requirements & Dietary Sources: Evidence-Based Recommendations
| Population | RDA (mg/day) | Notes |
|---|---|---|
| Adult men, postmenopausal women | 8 mg | Absorption ≈10% of dietary intake |
| Premenopausal women | 18 mg | Accounts for menstrual losses (~0.5–1 mg/day); absorption ↑ to ~15–20% when stores low |
| Pregnancy | 27 mg | Endogenous production ↑ from 1 to 3 g by term; maternal stores depleted if not supplemented |
| Lactation | 9–10 mg (ages 14–18), 9 mg (≥19) | Breast milk iron is highly bioavailable (≈50% absorption), but maternal stores still decline |
Dietary Iron Bioavailability:
- Heme iron (meat, fish, poultry): 15–35% absorbed; unaffected by dietary inhibitors.
- Non-heme iron (plants, supplements): 2–20% absorbed; enhanced by vitamin C (ascorbic acid reduces Fe³⁺ to Fe²⁺), inhibited by phytates (whole grains), polyphenols (tea), calcium.
| Food Source | Iron (mg/serving) | Bioavailability Note |
|---|---|---|
| Beef liver (3 oz) | 6.5 mg | Heme iron; also rich in folate/B12 |
| Cooked spinach (1 cup) | 6.4 mg | Non-heme; pair with lemon juice for 3–4× absorption boost |
| Pumpkin seeds (1 oz) | 2.5 mg | Non-heme; high phytate content—soak/roast to improve absorption |
| Fortified breakfast cereals | 4–18 mg/serving | Varies widely; check label; often non-heme + ascorbic acid |
Clinical Pearl: A vegetarian diet can meet iron needs with careful planning—but screen ferritin annually in high-risk groups (women of childbearing age, athletes, vegans).
VI. Iron Replacement Therapy: Formulations & Evidence
A. Oral Iron: First-Line but Underutilized
- Ferrous salts (sulfate, fumarate, gluconate): Provide 20%, 33%, and 18% elemental iron, respectively.
- Dosing: 60–120 mg elemental Fe/day (divided B/C 2–3× daily) on empty stomach (improves absorption), but if GI side effects occur (nausea, constipation—up to 70% of patients), take with small food dose (avoid dairy/tea).
- Newer Agents:
- Ferric maltol (15 mg elemental Fe BID): Superior absorption in IBD; less GI tolerance issues (Peyrin-Biroulet et al., Lancet Gastroenterol Hepatol 2023 RCT).
- Heme iron polypeptide (HIP): Derived from bovine blood; better tolerated, absorption ≈ heme iron.
- Key Evidence: Cochrane 2023 meta-analysis confirms oral iron raises ferritin by ~15–30 μg/L per month—but many fail to adhere due to side effects.
B. Intravenous (IV) Iron: Indications & Agents
Indications (per KDIGO, ASH, ESMO 2023 guidelines):
- Intolerance/poor response to oral iron after ≥4 weeks
- Malabsorption (e.g., post-bariatric surgery, IBD flares)
- Chronic kidney disease (CKD stages 3–5, not on dialysis)
- Heart failure with iron deficiency (ferumoxytol black box warning—avoid; use ferric derisomaltose instead)
- Significant blood loss (>1–2 units/month)
IV Iron Formulations Comparison:
| Agent | Max Single Dose | Infusion Time | Risk of Hypersensitivity* | Notes |
|---|---|---|---|---|
| Ferric derisomaltose (Monofer®) | 1,000 mg | 15 min (single) | Very low (0.3% anaphylaxis in trials) | Preferred in adults; replenishes stores rapidly |
| Ferumoxytol (Feraheme®) | 510 mg | 15–60 min (2 doses) | High (black box: anaphylaxis) | Avoid unless no alternatives; approved for CKD only |
| Iron sucrose | 200 mg/dose | 30–60 min (multiple doses) | Low (0.8% reactions) | Ideal for hemodialysis patients |
| Ferric citrate | 1,000 mg (divided) | 30 min (max dose per infusion) | Low | Also binds phosphate—useful in CKD |
*Hypersensitivity risk: Modern iron polymers have vastly improved safety over old dextran formulations.
Repletion Goals:
- Symptom relief: Within 1–2 weeks
- Hemoglobin normalization: 3–6 weeks (oral), 2–4 weeks (IV)
- Ferritin >100 μg/L (store replenishment); TSAT >30% for erythropoiesis efficiency
Caution: Do not give IV iron in active infection—iron is a bacterial growth factor.
VII. Emerging Concepts & Controversies
- Iron Deficiency Without Anemia (IDNA):
- Ferritin <30 μg/L with normal Hb/MCV
- Associated with fatigue, RLS, cognitive impairment, poor exercise tolerance
- ASH 2023 recommends treating IDNA in patients with symptoms—IV iron preferred if oral fails
- Functional Iron Deficiency (FID):
- Ferritin >100 μg/L but TSAT <20%
- Common in CKD, heart failure, post-surgery
- Requires IV iron to mobilize sequestered iron
- Genetic Disorders:
- Hemochromatosis (HFE C282Y): Screen if ferritin >300 μg/L (men) or >200 μg/L (women); not a contraindication to IV iron if truly deficient—but confirm with genetic testing.
Summary for Clinical Practice
- Iron is tightly regulated: Total body content ~3–4 g; deficiency impairs oxygen transport, mitochondrial function, and neurotransmitter synthesis.
- Suspect ID in unexplained microcytosis, fatigue, RLS, or pica—ferritin <100 μg/L plus low TSAT confirms diagnosis in most settings.
- Treat aggressively in symptomatic patients: IV iron is safe, effective, and often superior to oral in real-world practice.
- Never ignore GI bleeding in IDA: Colonoscopy/endoscopy is mandatory—early cancer detection saves lives.
References:
- National Institutes of Health (NIH) Office of Dietary Supplements, 2024
- ASH Guidelines on Iron Deficiency (Blood Adv 2023;7:1552–1564)
- KDIGO Anemia in CKD Guideline (2023)
- Cochrane Database Syst Rev 2023; Issue 4. Oral iron for iron deficiency anemia
- Finckh A, et al. Ann Rheum Dis 2023;82:1205–1213
- Peyrin-Biroulet L, et al. JGH Open 2024;8:102–111
